Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NPI-001 for Retinitis Pigmentosa in Usher Syndrome
NCT07290530Phase 3Not yet recruiting
- Sponsor
- Nacuity Pharmaceuticals
- Start
- Dec 2026
- Primary completion
- Jul 2029
01
Overview
A Phase 3 trial of N-acetylcysteine amide in retinitis pigmentosa (RP), Usher syndrome, sponsored by Nacuity Pharmaceuticals. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
N-acetylcysteine amide
03
Conditions
retinitis pigmentosa (RP)Usher syndrome
Beyond the preview
Go deeper on NCT07290530.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07290530.